Topline results from an open-label safety study investigating ONS-5010/Lytenava in the treatment of retinal diseases showed no unexpected safety results, according to a press release from Outlook Therapeutics.
The NORSE THREE study included 197 patients with varying retinal diseases in which anti-VEGF injections may be used as a treatment, the release said. Enrolled patients received three monthly intravitreal doses of ONS-5010 (bevacizumab-vikg).
Endpoints for the trial included frequency and incidence of treatment-emergent adverse events and an evaluation of changes in safety parameters, the
Uncategorized